Studies in the lab of Steven F. Ziegler, PhD, at BRI found that a specific cytokine could serve as a biomarker heralding the development of colon cancer – and holds promise as a therapeutic target to fight colorectal cancers.

In the study, the team found they could inhibit colorectal tumors by blocking TSLP, which suggests that the cytokine may control the progression of the cancer through the regulation of T cell function.

Evidence supports that screening for TSLP in the blood could indicate the development of colon cancer, which would make this cytokine a biomarker for the disease. Additionally, the study data suggest that TSLP blockade could provide a biologic and promising new therapy.

Learn more…